News | Coronavirus (COVID-19) | March 16, 2020| Dave Fornell, Editor

ESC Council on Hypertension Says ACE-I and ARBs Do Not Increase COVID-19 Mortality

The European Society of Cardiology (ESC) is recommending in novel coronavirus (COVID-19) patients not discontinuing angiotensin converting enzyme inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) used to control hypertension. 

March 16, 2020 — The European Society of Cardiology (ESC) issued a statement March 13 recommending in novel coronavirus (COVID-19, and now clinically referred to as SARS‐CoV‐2) patients not discontinuing angiotensin converting enzyme inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) used to control hypertension

Despite some early report theorizing these drugs might play a role to increase COVID-19 mortality, the Council on Hypertension of the ESC pointed out the lack of any evidence supporting harmful effect of ACE-I and ARB in the context of the pandemic COVID-19 outbreak.

According to case fatality rates reported by the American College of Cardiology (ACC) in COVID-19 patients, comorbid patients have materially higher than the average population. The ACC said hypertension elevates patient mortality risk to 6 percent. Read more on ACC COVID-19 recommendations for the cardiovascular care team.

The Council on Hypertension strongly recommends that physicians and patients should continue treatment with their usual anti-hypertensive therapy because there is no clinical or scientific evidence to suggest they cause any harm in COVID-19 infections.

Based on initial reports on COVID-19 patients in China and subsequent evidence since the outbreak, arterial hypertension may be associated with increased risk of mortality in hospitalized COVID-19 infected subjects. There was a hypothesis  suggesting this might be a potential adverse effect of ACE-i or ARBs. 

"It has been suggested, especially on social media sites, that these commonly used drugs may increase both the risk of infection and the severity of SARS-CoV2," explained Prof. Giovanni de Simone, chair of the ESC Council on Hypertension, who wrote the statement. "The concern arises from the observation that, similar to the coronavirus causing SARS, the COVID-19 virus binds to a specific enzyme called ACE2 to infect cells, and ACE2 levels are increased following treatment with ACE-i and ARBs." 

ESC said in the statement that because of the social media-related amplification, patients taking these drugs for their high blood pressure and their doctors have become increasingly concerned, and, in some cases, have stopped taking their ACE-I or ARB medications.

"This speculation about the safety of ACE-i or ARB treatment in relation to COVID-19 does not have a sound scientific basis or evidence to support it. Indeed, there is evidence from studies in animals suggesting that these medications might be rather protective against serious lung complications in patients with COVID-19 infection, but to date there is no data in humans," he said.

"There has been a lot of talk about the molecular and pathophysiology basis of the virus being mediated by the ACE-II receptors," said Thomas Maddox, M.D., MSc, FACC, the chairman of the American College of Cardiology (ACC) Science and Quality Committee, which recently created the ACC document on novel coronavirus (COVID-19) clinical guidance for the cardiovascular care team. "They are primarily in the lung, and that is why many people obviously have the pulmonary symptoms that are showing, but we know they are in the heart and intestine as well. We have started hearing reports of patients both domestically [in the U.S.] and overseas where they started to show signs of recovery from the lung disease and then all of a sudden appear to develop myocarditis or cardiomyopathy, and in some cases it is fatal."

He explained there was thinking that in the the expression of ACE-IIs, ACE-I inhibitors or ARBs might be able to inhibited the viral transport into the cells. However, the mechanisms behind the interactions of ACE-II and the ACI-Is and ARBs is very complex and there is no clear evidence that these drugs help inhibit, or aid the disease.

Read the related article COVID-19 Hydroxychloroquine Treatment Brings Prolonged QT Arrhythmia Issues.

This includes some background information on the ACE receptors — VIDEO: The Latest Data on COVID-19 and Cardiovascular Disease

Watch the VIDEO: What Cardiologists Need to Know about COVID-19 — Interview with Thomas Maddox, M.D., which discusses this subject in more detail.

Watch the VIDEO: Cancelling Non-essential Cardiac Procedures During the COVID-19 Outbreak — an interview with SCCT President Ehtisham Mahmud, M.D.,

For more information: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang

 

Related Cardiology Related COVID-19 Content:

Statins May Reduce COVID-19 Severity

First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients

No Evidence Supporting Discontinuing RAAS Inhibitors in COVID-19 Patients

 

ACC COVID-19 recommendations for the cardiovascular care team

VIDEO: What Cardiologists Need to Know about COVID-19 — Interview with Thomas Maddox, M.D.

The Cardiac Implications of Novel Coronavirus

ESC Council on Hypertension Says ACE-I and ARBs Do Not Increase COVID-19 Mortality

VIDEO: Imaging COVID-19 With Point-of-Care Ultrasound (POCUS)

 

CT Provides Best Diagnosis for Novel Coronavirus (COVID-19)

Radiology Lessons for Coronavirus From the SARS and MERS Epidemics

Deployment of Health IT in China’s Fight Against the COVID-19 Epidemic

Emerging Technologies Proving Value in Chinese Coronavirus Fight

Radiologists Describe Coronavirus CT Imaging Features

 

Coronavirus Update from the FDA

CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia

CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)

Chest CT Findings of Patients Infected With Novel Coronavirus 2019-nCoV Pneumonia 

 

Additional COVID-19 Resources for Clinicians:

   ACC COVID-19 Hub page   

   Johns Hopkins Coronavirus Resource Center with inteavtive map of cases in U.S. and worldwide 

   World Health Organization (WHO) COVID-19 situation reports

   World Health Organization (WHO) coronavirus information page

   U.S. Food and Drug Administration (FDA) COVID-19 information page

   Centers for Disease Control (CDC) COVID-19 information page

   Centers for Medicare and Medicaid Services (CMS) frequently asked questions and answers (FAQs) for healthcare providers regarding COVID-19 related payments

Related Content

Cardiologists are taking a closer look at the possible long-term cardiovascular effects on COVID long-hauler patients who still show symptoms long after they should be recovered from the virus. Getty Images

Cardiologists are taking a closer look at the possible long-term cardiovascular effects on COVID long-hauler patients who still show symptoms long after they should be recovered from the virus. Getty Images

Feature | Coronavirus (COVID-19) | January 22, 2021 | Dave Fornell, Editor
With nearly a year of experience with the...
A recent Society for Cardiovascular Angiography and Interventions (SCAI) survey found nearly 40 percent of Americans still do not feel safe going to the doctor's office while coronavirus is still a risk. Survey respondents also said they are more afraid of catching the virus than they are of a heart attack or stroke, which may delay critical treatment. Getty Images

A recent Society for Cardiovascular Angiography and Interventions (SCAI) survey found nearly 40 percent of Americans still do not feel safe going to the doctor's office while coronavirus is still a risk. Survey respondents also said they are more afraid of catching the virus than they are of a heart attack or stroke, which may delay critical treatment. Getty Images

News | Coronavirus (COVID-19) | January 18, 2021
January 18, 2021 — According to a new national survey released Jan.
Myocarditis among recovering COVID-19 athletes less common than previously reported

Myocarditis among recovering COVID-19 athletes appears to be less common than previously reported. Getty Images

News | Coronavirus (COVID-19) | January 12, 2021
January 11, 2021 — In a letter published in the December issue of the American Heart Association (AHA) ...
The AHA and American Medical Society for Sports Medicine are collaborating to evaluate impact of COVID on the hearts of athletes, improve detection and inform safe return to play. #COVID19

The AHA and American Medical Society for Sports Medicine are collaborating to evaluate impact of COVID on the hearts of athletes, improve detection and inform safe return to play. Getty Images

News | Coronavirus (COVID-19) | January 12, 2021
January 12, 2021 — The American Heart Association (AHA) and the Ameri...
While the FDA said the risk that SARS-CoV-2 virus mutations will only have a minor impact on testing accuracy is low, the agency singled out three tests are they had a higher concern. FDA warns PCR tests may be innaccurate with new UK virus varient.

While the FDA said the risk that SARS-CoV-2 virus mutations will only have a minor impact on testing accuracy is low, the agency singled out three tests are they had a higher concern.

Feature | Coronavirus (COVID-19) | January 08, 2021 | Dave Fornell, Editor
January 8, 2021 — The U.S.
Who Can Get the COVID-19 Vaccine? Roberto Lang, M.D., director of noninvasive cardiac imaging, University of Chicago Medical Center and former American Society of Echocardiography (ASE) president, received his first dose of the COVID vaccine in December. In addition to front line hospital workers, nursing home staff and residents also qualified for the first round of vaccinations. Right, Shannon Yaw, a nurse at a hard-hit nursing home in Michigan, received her first dose just before Christmas.

Roberto Lang, M.D., director of noninvasive cardiac imaging, University of Chicago Medical Center and former American Society of Echocardiography (ASE) president, received his first dose of the COVID vaccine in December. In addition to front line hospital workers, nursing home staff and residents also qualified for the first round of vaccinations. Right, Shannon Yaw, OTR/L, director of rehabilitation at a hard-hit nursing home in Michigan, received her first dose just before Christmas.

News | Coronavirus (COVID-19) | January 04, 2021 | Dave Fornell, Editor
The Centers for Disease Control and Prevention (CDC) Dec.
Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al.

Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al. 

Feature | Coronavirus (COVID-19) | December 23, 2020
December 23, 2020 — Three clinical trial platforms working together to test the effects of full doses of anticoagulan
The FDA December 18 issued an emergency use authorization (EUA) for a second COVID-19 vaccine from Moderna for use in individuals 18 years of age and older. #COVID19 #SARSCoV2 #Vaccine

The FDA December 18 issued an emergency use authorization (EUA) for a second COVID-19 vaccine from Moderna for use in individuals 18 years of age and older.

News | Coronavirus (COVID-19) | December 23, 2020
December 23, 2020 — The U.S.
Coronavirus SARS-CoV-2 colorized scanning electron micrograph of a cell (pink) heavily infected with SARS-CoV-2 virus particles (teal and purple), isolated from a patient sample. Image courtesy of NIAID. MIS-C Multisystem inflammatory syndrome in children. #COVID19

Coronavirus SARS-CoV-2 colorized scanning electron micrograph of a cell (pink) heavily infected with SARS-CoV-2 virus particles (teal and purple), isolated from a patient sample. Image courtesy of NIAID.

News | Coronavirus (COVID-19) | December 22, 2020
December 22, 2020 — An observational study has launched to evaluate the short- and long-term health outcomes of SARS-
The U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) Dec, 12 for the COVID-19 vaccine submitted by Pfizer Inc. in partnership with BioNTech Manufacturing GmbH. It is the first mRNA vaccine to gain an FDA clearance and the first COVID vaccine to gain FDA clearance.  #COVID #COVID19 #SARSCoV2 #vaccine #COVIDVaccine

The U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) Dec. 12 for the COVID-19 vaccine submitted by Pfizer Inc. in partnership with BioNTech Manufacturing GmbH. It is the first mRNA vaccine to gain an FDA clearance and the first COVID vaccine to gain FDA clearance. 

Feature | Coronavirus (COVID-19) | December 14, 2020 | Dave Fornell, Editor
December 14, 2020 — The U.S.